Pancreatic cancer has the lowest survival rate of all cancers and remains a leading cause of cancer death. Most patients do not survive the first year post-diagnosis and overall survival is only 6%. Approximately 600 people in B.C. will be diagnosed this year.

The survival rate has remained unchanged for decades. Despite being one of the deadliest cancers, a recent Cancer in Canada study reported that pancreatic cancer research is also one of the most underfunded, with only 0.1% of all charitable monies raised attributed specifically to this cause.

By raising awareness and funds, the Glotman·Simpson Cypress Challenge is helping to change the story and improve outcomes for future pancreatic cancer patients.

Every dollar we raise counts to improve future outcomes. 100% of the funds raised at the Cypress Challenge go toward pancreatic cancer research, one of the most underfunded cancers.

We #RideFor600  @CypChallenge



Pancreas Centre BC
Through a collaborative approach to improving care and survival for pancreatic cancer patients, the Pancreas Centre BC team of scientists and clinicians is leading a number of critical studies. This year advancements have included;

  • The establishment of a hereditary pancreatic cancer research program
  • Projects to uncover the cellular origin of the disease
  • The development of new drugs
  • Bringing new therapies options to patients sooner through clinical trials

The Pancreas Centre BC team is working to establish a Care Coordination and Support Program to provide optimum care for patients with this disease. More than 300 patients were involved last year from communities outside of Vancouver, ensuring all patients have access to the most advanced diagnostics and treatment options. Added patient supports are now in place with a nurse navigator at both the BC Cancer Agency and VGH – working to improve the quality of life for patients with pancreatic cancer.


Accelerating Progress
PANGEN: With support from the Cypress Challenge, the Pancreas Centre BC team is gearing up to launch an innovative new clinical study. The PanGen study will have immediate impact on patient care as those participating will undergo genomic analysis of their cancer. This will provide clinicians with critical detail as the team profiles the cancer to offer the most individualized care possible. Additionally, the genomic information will be collected to sub-type the disease.

Circulating Tumour DNA: research is underway to identify whether or not a blood test is a feasible method of detecting the cancer’s presence, recurrence, and response to treatment. This is a promising area of research with capacity to greatly improve the patient experience. 

Ambitious Goals Ahead
The scientists and clinicians aim to fully understand how pancreatic cancer develops and progresses. One of the key areas of research going forward will be potential screening methods to help catch the disease earlier. The team is also working to develop innovative new therapies to improve the length and quality of patient lives.